Metabolic and anthropometric consequences of interrruption of highly active antiretroviral therapy

AIDS

Volumn 14, Issue 13, 2000, Pages 1935-1942

  Hatano, Hiroyu ^a   Miller, Kirk D ^b   Yoder, Christian P ^b   Yanovski, Jack A ^b   Sebring, Nancy G ^b   Jones, Elizabeth C ^b   Davey Jr , Richard T ^a,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antiretroviral therapy; Fat redistribution; HAART; Hypercholesterolemia; Hyperlipidemia; Insulin resistance; Lipoatrophy; Lipodystrophy; Lipohypertrophy; Metabolic abnormalities

Indexed keywords

17 HYDROXYCORTICOSTEROID; ANTIRETROVIRUS AGENT; CHOLESTEROL; DELAVIRDINE; DIDANOSINE; GLUCOSE; HYDROCORTISONE; INDINAVIR; INSULIN; LAMIVUDINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MALE; METABOLIC DISORDER; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; CHOLESTEROL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROCORTISONE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPIDS; LIPODYSTROPHY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SKINFOLD THICKNESS; TRIGLYCERIDES;

EID: 0034622989     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200009080-00008     Document Type: Article

References (40)

1. Declining HIV/AIDS mortality in New York City
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
3. 'Buffalo hump' in men with HIV-1 infection
4. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving protease inhibitors
5. Visceral abdominal-fat accumulation associated with use of indinavir
6. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
7. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
8. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
9. Reaching a consensus: Lipodystrophy case definition
10. Fat distribution and metabolic changes in patients with HIV infection
11. Myocardial infarction in HIV-infected men receiving protease inhibitors
12. Coronary-heart-disease risk and impaired glucose tolerance: The Whitehall study
13. Combined effects of HDL cholesterol, triglyceride and total cholesterol concentrations on 18 year risk of atherosclerotic disease
14. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
15. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy
16. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
17. HIV nucleoside analogues: New adverse effects on mitochondria?
18. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
19. Lipodystrophy defined by a clinical score in HIV-infected men on highly-active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
20. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
21. Fasting hyperinsulinemia and increased waist-to-hip ratios in non- wasting individuals with AIDS
22. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
23. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
24. The homeostasis model in the San Antonio Heart Study
25. The metyrapone and dexamethasone suppression tests for the differential diagnosis of adrenocorticotropin-dependent Cushing syndrome: A comparison
26. Abdominal fat assessed by computed tomography: Sex difference in distribution
27. Computer tomography measurement of abdominal fat deposition in relation to anthropometry
28. Body fat assessed from total body density and its estimation from skinfold thickness: Measurements of 481 men and women aged from 16 to 72 years
29. Evaluation of a new air displacement plethysmograph for measuring human body composition
30. Clinical review 102: Type 2 diabetes mellitus: Update on diagnosis, pathophysiology, and treatment
31. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
32. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
33. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
34. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study